Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1992-12-18
1998-09-15
LeGuyader, John L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 8, 514 21, 424562, A61K 3830, A61K 3555
Patent
active
058078223
ABSTRACT:
The present invention relates to an improved method of treating osteopenias, particularly osteoporosis, in mammals comprising administering a therapeutically effective amount of a pharmaceutical formulation agent comprising the polypeptide Insulin-like Growth Factor II or an osteoblastic stimulating fragment thereof, either alone or in the presence of a potentiating amount of fluoride ion, and in a pharmaceutically acceptable carrier.
The invention further relates to a method of preventing osteopenias in a susceptible population of mammals consisting of administering a prophylactically effective amount of the pharmaceutical agent described above.
REFERENCES:
Perdue, 13th Int. Cancer Congress Part B Biol. of Cancer pp. 405-413 1983 "The Role of Somatomedin/Insulin Like Growth Factors and Their Receptors in Skeletal Growth and Fetal Development: a Mini Review".
Rinderknecht et al Proc Natl Acad Sci vol. 73 pp. 2365-2369 1976 "Polypeptide with Nonsuppressible Insulin-Like and Cell Growth Promoting Activities in Human Serum: Isoaltion, Chemical . . . ".
Rinderknecht et al FEBS Lett vol. 89(2) May 1978 "Primary Structure of Human Insulin-Like Growth Factor II".
Bennett et al Endocrinology vol. 115 pp. 1577-1583 1984 "Characteriztion of Insulin-Like Growth Factor I Receptors on Cultured Rat Bone Cells: . . . ".
Canalis J Clin Invest vol. 66 Oct. 1980 pp. 709-719 "Effect of Insulin Like Growth Factor I on DNA and Protein Synthesis in Cultured Rat Calvaria".
Baylink et al Clin Orthoped vol. 55 pp. 51-85 1967.
Schoenle et al. (1982) 64.sup.th Annual Necking Endocrine Society, Abstr. 325.
Frost et al. Bone & Mineral 18(1982) 227-236.
Postel-Vinay et al. Exper. Cell. Res. 148(1983) 105-116.
Bennett et al. J. Clin. Endocrinol. Metab. 59(1984) 701-704, Cited and Provided as BIOSIS Abstract No.: 75030087.
Schmid et al. Calcif. Tissue Int. 35(1983) 578-585, Cited as and Provided as BIOSIS Abstract No.: 77018221.
Potan et al. Biochem Biophys. Res. Comm. 119(1984) 359-364 (Feb.).
The Merck Manual of Diagnosis & Therapy Merck Research Labs, New Jersey, 1992, pp. 1357-1359.
British Biotechnology Ltd.
LeGuyader John L.
LandOfFree
Insulin-like growth factor II as a pharmaceutical agent in the t does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Insulin-like growth factor II as a pharmaceutical agent in the t, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Insulin-like growth factor II as a pharmaceutical agent in the t will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-86921